Loading
A phase 1/2 trial of Osimertinib, Pembrolizumab, Nivolumab and PM8002 in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06618287 by Bristol-Myers Squibb, with 416 participants planned, started 2025-02-04 and due to reach its primary completion in 2031-02-26. Interventions recorded: BMS-986507, Osimertinib, Pembrolizumab, Nivolumab and Pumitamig.
Shares PM8002, Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Bristol Myers Squibb, Nivolumab and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, Metastatic cancer (cancer that has spread) and the tag pipeline.